Mar 26, 2026 | Wave Crashes 58% on Obesity Data Miss; CVC Bids $12.6B for Recordati

Wave Life Sciences plunges 58% after WVE-007 higher-doseobesity data fails to separate from lower dose. CVC Capital Partners offers €52/share ($12.6B) to take Recordati private. Plus: Kodiak's Phase 3 GLOW2 diabetic retinopathy win, Corcept's relacorilant approval in ovarian cancer, and FDA "America First" user fee pushback.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Wave Life Sciences, WVE-007, obesity drug data, INLIGHT trial, Recordati, CVC Capital Partners, rare disease, take-private, Kodiak Sciences, tarcocimab, Zenkuda, GLOW2,diabetic retinopathy, Corcept Therapeutics, relacorilant, Lifyorli, ovarian cancer, Denali, Avlayah, Hunter syndrome, Alnylam, ATTR, user fees, America First, Pinnacle Medicines, oral peptide, M&A, Takeda